We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Endpoint for Diabetes Trials Remains Glycemic Control
Endpoint for Diabetes Trials Remains Glycemic Control
October 13, 2010
Despite the controversy surrounding GlaxoSmithKline’s (GSK) diabetes drug Avandia, sponsors will not have to worry, for now, about adding cardiovascular (CV) outcome as a primary endpoint for diabetes drugs they’re developing, according to FDA officials.